Page last updated: 2024-08-24

ibandronic acid and Bone Loss, Perimenopausal

ibandronic acid has been researched along with Bone Loss, Perimenopausal in 184 studies

Research

Studies (184)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (4.89)18.2507
2000's97 (52.72)29.6817
2010's62 (33.70)24.3611
2020's16 (8.70)2.80

Authors

AuthorsStudies
Feng, D; Ke, L; Liu, J; Luo, F; Mori, T; Wan, Y; You, R; Yu, G; Zhang, Y1
Baek, KH; Kang, MI; Kim, J; Kim, KM; Lim, S; Min, YK1
Dong, S; Hu, Y; Ke, Z; Lv, M; Shen, J; Song, L; Wu, K; Xu, K; Yuan, Y1
Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M1
Kobayakawa, T; Miyazaki, A; Nakamura, Y; Takahashi, J1
Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M1
Ehrenstein, V; Kafatos, G; Neasham, D; O'Kelly, J; Pedersen, AB; Risbo, N1
Alves, C; Batel-Marques, F; Donato, A; Mendes, D; Oliveira, T; Penedones, A1
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T1
Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR1
Bao, X; Gao, L; Li, Y; Liu, C; Tian, Y; Wang, K1
Chen, LH; Ma, WJ; Wang, WY; You, RX1
Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O1
Chiu, WY; Lin, CJ; Reginster, JY; Tsai, KS; Yang, WS1
Eastell, R; Fontalis, A1
Betsch, M; Colarossi, G; Eschweiler, J; Maffulli, N; Migliorini, F; Tingart, M1
Baek, GH; Gong, HS; Noh, JH; Roh, YH1
Boyanov, M; Intorcia, M; Petkova, R; Petranova, T; Psachoulia, E; Shinkov, A1
Bradburn, M; Eastell, R; Gossiel, F; McCloskey, EV; Naylor, KE; Paggiosi, MA; Peel, NFA; Walsh, JS1
Lee, DR; Lee, J1
Hongo, M; Horikawa, A; Kasukawa, Y; Kodama, H; Miyakoshi, N; Shimada, Y1
Brzeziańska, E; Cegłowska, A; Liberski, PP; Rieske, P; Sewerynek, E; Stêpień-Kłos, W; Stuss, M1
Black, DM; Burghardt, AJ; Majumdar, S; Palermo, L; Schafer, AL; Sellmeyer, DE; Shoback, DM1
Cerdá, D; Gifre, L; Guañabens, N; Monegal, A; Muxí, Á; Parés, A; Peris, P1
Aleksandrova, EN; Alekseeva, LI; Demin, NV; Sharapova, EP; Smirnov, AV; Taskina, EA; Zaitseva, EM1
Amling, M; Felsenberg, D; Hadji, P; Hofbauer, LC; Kandenwein, JA; Kurth, A1
Barr, C; Day, BM; Felsenberg, D; Harris, S; Masanauskaite, D; Miller, PD; Recker, RR; Reginster, J; Silverman, S1
Caffarelli, C; Franci, BM; Gonnelli, S; Lucani, B; Nuti, R; Pondrelli, C; Tanzilli, L1
Hviid, A; Pasternak, B; Svanström, H1
Bolognese, MA; Bone, HG; Bonnick, S; Brown, JP; Dakin, P; Ferreira, I; Hall, J; Ho, PR; Recknor, C; Roux, C; van den Bergh, JP; Wagman, RB1
Günther, B; Hans, D; Lippuner, K; Perrelet, R; Popp, AW; Senn, C1
Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S1
Eastell, R; McCloskey, E; Paggiosi, MA; Peel, N; Walsh, JS1
Alam, SS; Baig, M; Tariq, S1
Hagino, H; Hashimoto, J; Matsunaga, M; Nakamura, T; Tobinai, M; Yoshida, S1
Hashimoto, J; Iida, S; Kawanishi, T; Nakai, K; Tobinai, M1
Fuksa, L; Horak, P; Ladova, K; Matoulkova, P; Palicka, V; Stepan, J; Touskova, T; Vytrisalova, M1
Agodoa, I; Bonnick, S; Brown, JP; Ferreira, I; Ho, PR; Palacios, S; Van den Bergh, JP1
Joa, KL; Jung, HY; Kim, CH; Kim, HS; Kim, MO; Kim, YJ; Kwon, SY1
Gambhir, JK; Goel, N; Rajaram, S; Rathi, V; Singh, N; Srividhya, NB1
Eastell, R; Gossiel, F; Jacques, RM; McCloskey, EV; Naylor, KE; Paggiosi, M; Peel, NF; Walsh, JS1
Buondonno, I; D'Amelio, P; D'Amico, L; Fornelli, G; Isaia, GC; Lucchiari, M; Marchetti, M; Roato, I; Sassi, F; Spertino, E1
Di Bonito, M; Ferretti, V; Giampà, E; Nuvoli, G; Paoletti, F; Piazzini, M; Ranieri, M; Tuveri, MA; Vinicola, V1
Adami, S; Gatti, D; Rossini, M; Viapiana, O2
Jędrzejczyk, S; Król, I; Sewerynek, E; Stępień-Kłos, W; Stuss, M1
Dohke, T; Iba, K; Kanaya, K; Sasaki, K; Takada, J; Wada, H; Yamashita, T; Yoshizaki, T1
Harris, ST; Insinga, R; Lewiecki, EM; Modi, A; Sajjan, S; Weaver, J1
Jiang, LA; Leder, BZ; Lee, H; Tsai, JN1
Buffat, H; Curkovic, I; Lippuner, K; Popp, AW; Popp, PF; Senn, C; Senn, R1
Bruyère, O; Neuprez, A; Reginster, JY1
Kastelan, D; Korsic, M; Vlak, T1
Adachi, JD; Adami, S; Cooper, C; Cranney, A; Delmas, PD; Miller, PD; Papapoulos, S; Reginster, JY; Sambrook, PN; Silverman, S; Siris, E; Wells, GA; Yetisir, E1
Burkiewicz, JS; Fit, KE; Griffin, BL; Meyer, CM1
Burge, RT; Lindsay, R; Marshall, DA; Tosteson, AN1
Davies, RY; Engelke, K; Fitzpatrick, LA; Fuerst, T; Genant, HK; Keaveny, TM; Kivitz, A; Kopperdahl, DL; Lewiecki, EM1
Body, JJ1
Bolognese, MA; McClung, MR; Miller, PD; Recker, RR; Sedarati, F1
Altabas, V; Crncevic Orlic, Z; Kastelan, D; Kolak, Z; Korsic, M; Lozo, P; Milas Ahic, J; Miskic, B; Stamenkovic, D; Vlak, T1
Emkey, RD1
Frampton, JE; Perry, CM1
Binkley, N; Dasic, G; Kohles, JD; Santiago, N; Silverman, SL; Simonelli, C; Sunyecz, JA1
Bilezikian, JP1
Lakatos, P1
Bachmann, GA; Binkley, N; Derman, RJ; Greenwald, M; Kohles, JD; Martens, MG; Silverman, SL1
Bolognese, M; Borges, JL; Cosman, F; Delmas, PD; Emkey, R; Epstein, S; Neate, C; Ragi-Eis, S; Recknor, C; Sedarati, F; Zerbini, CA1
Cotté, FE; Fardellone, P; Gaudin, AF; Mercier, F; Roux, C1
Bachmann, G; Bonnick, SL; Civitelli, R; Kohles, JD; Martens, M; Silverman, S; Tanner, SB1
Amling, M; Kurth, A1
Abelson, A; Gold, DT; Lange, JL; Ringe, JD; Thomas, T1
Byun, DW; Choi, WH; Chung, DJ; Chung, HY; Chung, YS; Kang, MI; Kim, GS; Kim, YK; Kwon, NH; Lee, IK; Lee, YS; Lim, SK; Min, YK; Park, IH; Park, JH; Shin, CS; Shong, MH; Yoon, HK1
Babbitt, A; Derman, R; Kohles, JD1
Li, M; Liu, DG; Liu, JL; Meng, XW; Xia, WB; Xing, XP; Zhang, ZL1
Bonvoisin, B; Czerwinski, E; Felsenberg, D; Langdahl, B; Masanauskaite, D; Recker, RR; Rowell, L; Ste-Marie, LG1
Hommann, M; Kaemmerer, D; Lehmann, G; Settmacher, U; Wolf, G1
Dasic, G; Davies, RY; Engelke, K; Fuerst, T; Genant, HK1
Cooper, C; Hartl, F; Lewiecki, EM; Mehta, D; Papapoulos, SE; Thompson, E1
Adam, JM; Albert, A; Cañete, A; de la Rosa, M; Gamilla, Z; Hsu, HC; Kung, AW; Lan, JL; Leerapan, T; Lin, HY; Lin, RM; Luevitoonvechkij, S; Navarra, S; Ngarmukos, S; Rachman, IA; Roeshadi, D; Rojanasthien, S; Songpatanasilp, T; Soong, YK; Soontrapa, S; Torralba, T; Tsai, K; Tu, ST; Vanbelle, S; Yuktanandana, P1
Cole, R1
Glendenning, P; Inderjeeth, CA; Lee, S1
Adami, S; Delmas, PD; Huss, H; Miller, PD; Patel, KM; Recker, RR; Schimmer, RC1
Bakula, M; Car, D; Crncevic-Orlic, Z; Dusek, T; Dzubur, F; Gradiser, M; Grubisic, F; Jajic, Z; Kadojic, M; Kastelan, D; Korsic, M; Kuster, Z; Labar, L; Lozo, P; Mijic, S; Miskic, B; Nikolic, T; Pekez, M; Poljicanin, T; Radman, M; Radovic, E; Strizak-Ujevic, M; Tajsic, G; Vlak, T; Vugrinec, M1
Carranza-Lira, S; García-Hernández, P; Motta-Martínez, E1
Jones, G; Winzenberg, T1
Backa, T; Duraj, V; Rapushi, E; Roshi, E; Zoto, A1
Carter, D; Churchill, W; Clapp, M; Reddy, P; Slovik, D; Yeh, Y1
Dubourg, G; Giraudeau, B; Perrodeau, E; Ravaud, P; Rouanet, S; Roux, C1
Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF1
Jonkanski, I; Mautalen, C; Miller, PD; Ragi-Eis, S; Ramirez, F1
Czerwinski, E; Kenwright, A; Lakatos, P; Lorenc, R; Masanauskaite, D; Miller, PD; Recker, RR; Reginster, JY; Riis, BJ; Stakkestad, JA1
Aljinović, J; Bakula, M; Car, D; Crnčević-Orlić, Z; Dušek, T; Džubur, F; Gradišer, M; Grubišić, F; Jajić, Z; Kadojić, M; Kaštelan, D; Koršić, M; Kuster, Z; Labar, L; Lozo, P; Mijić, S; Miškić, B; Nikolić, T; Pekez, M; Poljičanin, T; Radman, M; Radović, E; Strižak-Ujević, M; Tajšić, G; Vlak, T; Vugrinec, M1
Bianchi, G; Burdeska, A; Czerwinski, E; Felsenberg, D; Kenwright, A; Recker, RR1
Lee, YH; Song, GG1
Armbrecht, G; Beller, G; Bock, O; Börst, H; Degner, C; Felsenberg, D; Martus, P; Roth, HJ1
Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH1
Criswell, DF; Dave, M1
Black, DM; Eastell, R; Hietpas, J; Palermo, L; Schafer, AL; Sellmeyer, DE; Shoback, DM1
Bala, Y; Boivin, G; Kohles, J; Recker, RR1
Yates, J1
Kraenzlin, CA; Kraenzlin, ME; Lardelli, P; Meier, C; Sieber, P1
Bauss, F; Schimmer, RC1
Christiansen, C; Mahoney, P; McClung, MR; Schimmer, RC; Tankó, LB1
Baumann, M; Christgau, S; Christiansen, C; Hoyle, N; Lehmann, HJ; Moelgaard, A; Mouritzen, U; Qvist, P; Tankó, LB; Warming, L; Wieczorek, L1
Papapoulos, SE1
Burdeska, A; Christiansen, C; Czerwiński, E; Felsenberg, D; Hughes, C; Jonkanski, I; Tankó, LB1
Benevolenskaya, LI; Burdeska, A; Jonkanski, I; Mahoney, P; Nordby, A; Oefjord, E; Skag, A; Stakkestad, JA; Stepan, JJ1
Bianchi, G; Cooper, C; Emkey, RD; Hawker, G; McDonald, RH; Schimmer, RC; Wilson, K1
Adami, S; Crepaldi, G; Filipponi, P; Sartori, L1
Bonvoisin, B; Chesnut, CH; Hughes, C; Mahoney, P; Meunier, PJ; Recker, RR; Schimmer, RC; Weinstein, RS1
Burdeska, A; Cauley, JA; Chesnut, CH; Ensrud, KE; McClung, MR; Mills, T; Recker, R; Wasnich, RD1
Kuwahara, T; Suzuki, M; Tanaka, Y; Yamada, T1
Landais, P; Maravic, M1
Alexandersen, P; Bagger, YZ; Christiansen, C; Qin, G; Tankó, LB1
Chesnut, CH; Christiansen, C; Delmas, PD; Felsenberg, D; Gilbride, J; Hoiseth, A; Huss, H; Recker, R; Schimmer, RC; Skag, A; Stakkestad, JA1
Gieschke, R; Goggin, T; Jacqmin, P; Pillai, G; Schimmer, RC; Steimer, JL1
Goto, H; Inaba, M1
Chapurlat, RD1
Wallace, DJ1
Adami, S; Bolognese, MA; Bonvoisin, B; Civitelli, R; Cooper, C; Delmas, PD; Dumont, E; Felsenberg, D; Kendler, DL; McClung, MR; Miller, PD; Recker, RR; Reginster, JY; Stakkestad, JA1
Barrett, J; Bonvoisin, B; Dumont, E; Reginster, JY; Wilson, KM1
Bolognese, MA; Bonvoisin, B; Cooper, C; Delmas, PD; Felsenberg, D; Hughes, C; Kendler, DL; Lewiecki, EM; Luckey, M; Macovei, L; Mairon, N; McClung, MR; Miller, PD; Recker, RR; Reginster, JY; Stakkestad, JA1
McClung, M1
Rackoff, PJ; Sebba, A1
Armbrecht, G; Felsenberg, D; Miller, P; Papapoulos, SE; Schimmer, RC; Wilson, K1
Ettinger, MP; Felsenberg, D; Harris, ST; Hiltbrunner, V; Miller, PD; Schimmer, RC; Skag, A; Wasnich, R; Wilson, K1
Reginster, JY3
Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB1
Adami, S; Bonvoisin, B; Christiansen, C; Cooper, C; Delmas, PD; Drezner, MK; Emkey, R; Felsenberg, D; Greenwald, M; Lakatos, P; Mairon, N; Miller, PD; Reginster, JY; Rowell, L; Silverman, SL; Stepan, JJ1
Beusterien, K; Devas, V; Emkey, R; Kivitz, A; Koltun, W; Masanauskaite, D; Seidman, L1
Delaney, MF1
Polk, B1
Neuprez, A; Rabenda, V; Reginster, JY1
Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM1
Reid, DM1
Dawson-Hughes, B; Gass, M1
Adami, S; Bolognese, M; Christiansen, C; Civitelli, R; Delmas, PD; Drezner, MK; Felsenberg, D; Hughes, C; Masanauskaite, D; Recker, RR; Reginster, JY; Reid, DM; Sambrook, P; Stakkestad, JA; Strugala, C; Ward, P1
Pyon, EY1
Brankin, E; Cooper, A; Drake, J1
Epstein, S; Friend, K; Zaidi, M1
Chesnut, CH1
Chapurlat, RD; Delmas, PD1
Croom, KF; Scott, LJ1
Langdahl, B; Mosekilde, L; Vestergaard, P1
Kessenich, CR1
Gieschke, R; Reginster, JY1
Cooper, A1
Gold, DT; Safi, W; Trinh, H1
Papapoulos, SE; Schimmer, RC1
Botsis, D; Christodoulakos, G; Lambrinoudaki, I1
Armamento-Villareal, R; Civitelli, R; Napoli, N1
Maricic, M1
Díaz-Curiel, M; Moro Alvarez, MJ1
McHorney, CA; Weiss, TW1
Civitelli, R; Emkey, R; Strampel, W1
Byrjalsen, I; Christiansen, C; Karsdal, MA; Leeming, DJ; Qvist, P1
Rizzoli, R1
Epstein, S; Miller, PD; Reginster, JY; Sedarati, F1
Blumentals, WA; Harris, ST; Miller, PD1
Chesnut, CH; Epstein, S; Harris, ST; Kohles, JD; Zaidi, M1
Barrett-Connor, E; Bourgeois, P; Devas, V; Fardellone, P; Hadji, P; Licata, A; Masanauskaite, D; Minne, H; Pfeifer, M1
Málek, Z1
Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G1
Lakatos, P; Lorenc, R; Neate, C; Reginster, JY; Sedarati, F; Stakkestad, JA1
Adami, S; Civitelli, R; Czerwinski, E; Delmas, PD; Eisman, JA; Felsenberg, D; Hughes, C; Mairon, N; Masanauskaite, D; Prince, R; Recker, RR; Recknor, C; Reginster, JY; Reid, DM; Zaidi, M1
Kastelan, D; Vlak, T1
Christiansen, C; Clemmesen, B; Ravn, P; Riis, BJ1
Schlosser, K; Scigalla, P1
Burckhardt, P1
Burckhardt, P; Huss, H; Juttmann, JR; Kriegbaum, H; Mulder, H; Schöter, KH; Thiébaud, D1
Browning, M; Chesnut, CH; Gaffney, EV; Schöter, KH; Ulrich, U1
Alexandersen, P; Bjarnason, NH; Christgau, S; Christiansen, C; Fledelius, C; Herling, C; Qvist, P; Ravn, P; Rosenquist, C1
Balfour, JA; Dooley, M1
Alexandersen, P; Møllgaard, A; Ravn, P1
Bagger, Y; Christiansen, C; Ise, J; Riis, BJ; von Stein, T1
Christiansen, C; Neugebauer, G; Ravn, P1
Ravn, P1

Reviews

61 review(s) available for ibandronic acid and Bone Loss, Perimenopausal

ArticleYear
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
    Medical science monitor : international medical journal of experimental and clinical research, 2022, Apr-17, Volume: 28

    Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures

2022
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2023, Mar-01, Volume: 29, Issue:2

    Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Observational Studies as Topic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid

2023
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Calcified tissue international, 2023, Volume: 112, Issue:6

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome

2023
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:17

    Topics: Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Teriparatide; Zoledronic Acid

2023
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
    Bone, 2020, Volume: 136

    Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal

2020
Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis.
    Journal of orthopaedic surgery and research, 2021, Aug-27, Volume: 16, Issue:1

    Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Pharmaceutical Preparations

2021
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:1

    Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; United States

2014
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:7

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Hip Joint; Humans; Ibandronic Acid; Injections, Subcutaneous; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptides; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors

2014
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
    Journal of endocrinological investigation, 2014, Volume: 37, Issue:8

    Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency

2014
The use of bisphosphonates in women: when to use and when to stop.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:16

    Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid

2015
Ibandronate in profile: drug characteristics and clinical efficacy.
    Expert opinion on drug metabolism & toxicology, 2008, Volume: 4, Issue:7

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal

2008
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2

    Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome

2009
[Update on treatment of postmenopausal osteoporosis].
    Revue medicale de Bruxelles, 2008, Volume: 29, Issue:4

    Topics: Bone Resorption; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Zoledronic Acid

2008
Quarterly intravenous ibandronate for postmenopausal osteoporosis.
    Women's health (London, England), 2008, Volume: 4, Issue:3

    Topics: Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Treatment Outcome

2008
Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
    Drugs, 2008, Volume: 68, Issue:18

    Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic

2008
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    The American journal of medicine, 2009, Volume: 122, Issue:2 Suppl

    Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid

2009
[Ibandronate in the treatment of postmenopausal osteoporosis].
    Lege artis medicinae : uj magyar orvosi hirmondo, 2008, Volume: 18, Issue:10

    Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2008
Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Clinical therapeutics, 2009, Volume: 31, Issue:7

    Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis, Postmenopausal

2009
Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.
    Women's health (London, England), 2009, Volume: 5, Issue:5

    Topics: Bone Density; Bone Density Conservation Agents; Cervical Vertebrae; Diphosphonates; Humans; Ibandronic Acid; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Thoracic Vertebrae

2009
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials.
    International journal of clinical practice, 2010, Volume: 64, Issue:6

    Topics: Aged; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risk Factors

2010
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:3

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome

2011
Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    The Korean journal of internal medicine, 2011, Volume: 26, Issue:3

    Topics: Administration, Oral; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Preference; Radiography; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome

2011
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spine

2013
Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Clinical therapeutics, 2003, Volume: 25, Issue:1

    Topics: Administration, Oral; Biomarkers; Bone Density; Bone Resorption; Clinical Trials, Phase II as Topic; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Time Factors

2003
Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.
    International journal of clinical practice, 2003, Volume: 57, Issue:5

    Topics: Administration, Oral; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Osteoporosis, Postmenopausal

2003
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
    Aging clinical and experimental research, 2003, Volume: 15, Issue:4

    Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Zoledronic Acid

2003
[Ibandronate].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2

    Topics: Animals; Bone Density; Bone Resorption; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Ibandronic Acid; Osteoclasts; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Spinal Fractures

2004
A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
    British journal of clinical pharmacology, 2004, Volume: 58, Issue:6

    Topics: Administration, Oral; Biomarkers; Bone Resorption; Clinical Trials as Topic; Collagen; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Humans; Ibandronic Acid; Infusions, Intravenous; Models, Biological; Osteoporosis, Postmenopausal; Peptides; Treatment Outcome

2004
[Ibandronate as a new therapeutic agent for osteoporosis].
    Clinical calcium, 2005, Volume: 15, Issue:1

    Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic

2005
Rapid prevention of vertebral fractures associated with osteoporosis.
    Orthopedics, 2005, Volume: 28, Issue:3

    Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid

2005
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:2

    Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase I as Topic; Diphosphonates; Dogs; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Rats; Spinal Fractures

2006
Use of highly potent bisphosphonates in the treatment of osteoporosis.
    Current osteoporosis reports, 2003, Volume: 1, Issue:3

    Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Severity of Illness Index; Treatment Outcome

2003
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
    Treatments in endocrinology, 2005, Volume: 4, Issue:4

    Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid

2005
Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:13

    Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic

2005
Review of treatment modalities for postmenopausal osteoporosis.
    Southern medical journal, 2005, Volume: 98, Issue:10

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency

2005
Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Current pharmaceutical design, 2005, Volume: 11, Issue:28

    Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal

2005
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
    American journal of obstetrics and gynecology, 2006, Volume: 194, Issue:2 Suppl

    Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Perimenopause; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D

2006
Adherence, patient preference and dosing frequency: understanding the relationship.
    Bone, 2006, Volume: 38, Issue:4 Suppl 1

    Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome

2006
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
    Maturitas, 2006, Apr-20, Volume: 54, Issue:1

    Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bone; Gastrointestinal Diseases; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid

2006
Once-monthly dosing: an effective step forward.
    Bone, 2006, Volume: 38, Issue:4 Suppl 1

    Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Pilot Projects; Placebos; Randomized Controlled Trials as Topic

2006
Preventing osteoporosis-related fractures: an overview.
    The American journal of medicine, 2006, Volume: 119, Issue:4 Suppl 1

    Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Humans; Ibandronic Acid; Motor Activity; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Teriparatide; United States; Vitamin D

2006
Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Clinical therapeutics, 2006, Volume: 28, Issue:4

    Topics: Aged; Bone Density Conservation Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal

2006
Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.
    Drugs, 2006, Volume: 66, Issue:10

    Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2006
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:4

    Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid

2006
Intravenous ibandronate: in the treatment of osteoporosis.
    Drugs, 2006, Volume: 66, Issue:12

    Topics: Animals; Area Under Curve; Bone and Bones; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Half-Life; Humans; Ibandronic Acid; Injections, Intravenous; Metabolic Clearance Rate; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Tissue Distribution

2006
Fracture prevention in postmenopausal women.
    Clinical evidence, 2006, Issue:15

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D

2006
Ibandronate (boniva) offers new options for osteoporosis.
    The Nurse practitioner, 2006, Volume: 31, Issue:10

    Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Intestinal Absorption; Metabolic Clearance Rate; Osteoporosis, Postmenopausal; Patient Selection; Treatment Outcome; United States

2006
[Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].
    Revue medicale de Liege, 2006, Volume: 61, Issue:11

    Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance

2006
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
    Annals of the rheumatic diseases, 2007, Volume: 66, Issue:7

    Topics: Administration, Oral; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Treatment Outcome

2007
Bisphosphonates.
    Annals of the New York Academy of Sciences, 2006, Volume: 1092

    Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid

2006
New and emerging treatments for osteoporosis.
    Current opinion in rheumatology, 2007, Volume: 19, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Patient Compliance; RANK Ligand; Zoledronic Acid

2007
Pharmacological treatment of osteoporosis for people over 70.
    Aging clinical and experimental research, 2007, Volume: 19, Issue:3

    Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D

2007
Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Drug safety, 2007, Volume: 30, Issue:9

    Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid

2007
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
    Current medical research and opinion, 2008, Volume: 24, Issue:1

    Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risk Factors; Time Factors

2008
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
    Annals of the New York Academy of Sciences, 2007, Volume: 1117

    Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Drug Design; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Proportional Hazards Models; Time Factors

2007
[The benefit from ibandronate in the treatment of postmenopausal osteoporosis].
    Vnitrni lekarstvi, 2007, Volume: 53, Issue:10

    Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2007
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
    Minerva endocrinologica, 2007, Volume: 32, Issue:4

    Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D

2007
[Does ibandronate (Bonviva) have an impact on non-vertebral fractures?].
    Reumatizam, 2007, Volume: 54, Issue:2

    Topics: Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2007
Ibandronate in oncology.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Neoplasms; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic

1997
Ibandronate.
    Drugs, 1999, Volume: 57, Issue:1

    Topics: Animals; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Neoplasms; Osteitis Deformans; Osteoporosis, Postmenopausal

1999
Bisphosphonates for prevention of postmenopausal osteoporosis.
    Danish medical bulletin, 2002, Volume: 49, Issue:1

    Topics: Alendronate; Biomarkers; Bone Density; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic

2002

Trials

71 trial(s) available for ibandronic acid and Bone Loss, Perimenopausal

ArticleYear
Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial.
    BMC endocrine disorders, 2022, Apr-11, Volume: 22, Issue:1

    Topics: Bone Density; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Prospective Studies; Treatment Outcome

2022
Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
    Bone, 2022, Volume: 162

    Topics: Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Prospective Studies

2022
Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
    Journal of bone and mineral metabolism, 2018, Volume: 36, Issue:5

    Topics: Administration, Intravenous; Administration, Oral; Alendronate; Bone Density Conservation Agents; Demography; Diphosphonates; Drug Administration Schedule; Female; Health Education; Humans; Ibandronic Acid; Injections, Intravenous; Medication Adherence; Middle Aged; Multivariate Analysis; Osteoporosis, Postmenopausal; Radius Fractures

2018
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, Volume: 29, Issue:6

    Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Hip Joint; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Withholding Treatment

2018
A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis.
    Medicine, 2019, Volume: 98, Issue:6

    Topics: Administration, Intravenous; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Prospective Studies; Treatment Outcome

2019
Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:5

    Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cholecalciferol; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Female; Gene Expression Regulation; Humans; Ibandronic Acid; Leukocytes, Mononuclear; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; RNA, Messenger; Thiophenes

2013
Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:10

    Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Finite Element Analysis; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Radius; Tibia; Tomography, X-Ray Computed; Weight-Bearing

2013
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6

    Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Cirrhosis, Biliary; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Treatment Outcome

2013
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Analgesics; Bone Density Conservation Agents; Diphosphonates; Drug Utilization; Female; Humans; Ibandronic Acid; Injections, Intravenous; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Motor Activity; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Treatment Outcome

2014
Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women.
    Bone, 2014, Volume: 61

    Topics: Administration, Intravenous; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Carotid Intima-Media Thickness; Diphosphonates; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Ibandronic Acid; Imidazoles; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid

2014
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:12

    Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Lower Extremity; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Upper Extremity

2014
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
    Calcified tissue international, 2014, Volume: 95, Issue:6

    Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid

2014
Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment.
    Clinical pharmacokinetics, 2015, Volume: 54, Issue:3

    Topics: Biomarkers, Pharmacological; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Collagen Type I; Computer Simulation; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Models, Biological; Osteoporosis, Postmenopausal; Peptides

2015
Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Risedronic Acid; Treatment Outcome

2015
Comparison of antiresorptive effect of hormone therapy and ibandronate in postmenopausal osteoporotic women by assessing type I collagen C-telopeptide levels.
    Post reproductive health, 2015, Volume: 21, Issue:2

    Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Ibandronic Acid; India; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Prospective Studies; Risk Assessment; Treatment Outcome

2015
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016, Volume: 27, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Premenopause; Reference Values; Risedronic Acid; Treatment Outcome

2016
Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, Volume: 26, Issue:12

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Primary; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Proto-Oncogene Proteins; RNA, Messenger; T-Lymphocytes; Vitamin D; Wnt Proteins

2015
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Bone, 2017, Volume: 98

    Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Teriparatide; Zoledronic Acid

2017
Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:1

    Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Finite Element Analysis; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Tomography, X-Ray Computed

2009
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    Bone, 2009, Volume: 44, Issue:3

    Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Treatment Outcome

2009
Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
    Clinical rheumatology, 2009, Volume: 28, Issue:3

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires; Time Factors

2009
Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:9

    Topics: Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Prospective Studies; Treatment Outcome

2009
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Southern medical journal, 2009, Volume: 102, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastroesophageal Reflux; Heartburn; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid

2009
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Clinical therapeutics, 2009, Volume: 31, Issue:4

    Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Treatment Outcome

2009
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Calcified tissue international, 2009, Volume: 85, Issue:5

    Topics: Aged; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Korea; Middle Aged; Osteoporosis, Postmenopausal; Patient Preference; Peptides; Prospective Studies; Risedronic Acid

2009
Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Journal of bone and mineral metabolism, 2010, Volume: 28, Issue:3

    Topics: Aged; Alkaline Phosphatase; Biomarkers; Body Height; Bone Density; Bone Density Conservation Agents; Bone Resorption; China; Collagen Type I; Diphosphonates; Female; Femur; Femur Neck; Humans; Ibandronic Acid; Infusions, Intravenous; Lumbar Vertebrae; Middle Aged; Muscular Diseases; Osteoporosis, Postmenopausal; Pain; Peptides; Time Factors

2010
Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study.
    Bone, 2010, Volume: 46, Issue:3

    Topics: Aged; Bone and Bones; Bone Density; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal

2010
Treatment of osteoporosis after liver transplantation with ibandronate.
    Transplant international : official journal of the European Society for Organ Transplantation, 2010, Volume: 23, Issue:7

    Topics: Absorptiometry, Photon; Adult; Aged; Alkaline Phosphatase; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Transplantation; Male; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone

2010
Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
    Bone, 2010, Volume: 46, Issue:6

    Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femur Neck; Hip Joint; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Spine

2010
Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women.
    International journal of rheumatic diseases, 2009, Volume: 12, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction

2009
Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
    Calcified tissue international, 2010, Volume: 87, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Spinal Fractures

2010
Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.
    Endocrine research, 2010, Volume: 35, Issue:4

    Topics: Aged; Bone Density Conservation Agents; Chi-Square Distribution; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Quality of Life; Surveys and Questionnaires

2010
[Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
    Ginecologia y obstetricia de Mexico, 2010, Volume: 78, Issue:6

    Topics: Administration, Oral; Aged; Biofeedback, Psychology; Biomarkers; Bone Density Conservation Agents; Calcium; Chile; Collagen Type I; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ibandronic Acid; Mexico; Middle Aged; Osteoporosis, Postmenopausal; Pain; Patient Compliance; Patient Satisfaction; Peptides; Prospective Studies; Vitamin D

2010
Monitoring of bone turnover markers does not improve persistence with ibandronate treatment.
    Joint bone spine, 2012, Volume: 79, Issue:4

    Topics: Biomarkers; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Diphosphonates; Drug Monitoring; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies

2012
Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.
    Bone, 2011, Volume: 49, Issue:6

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Ibandronic Acid; Injections, Intravenous; Kidney Diseases; Kidney Function Tests; Osteoporosis, Postmenopausal; Risk Factors

2011
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:6

    Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome

2012
Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:6

    Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome

2012
Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
    Bone, 2012, Volume: 50, Issue:1

    Topics: Absorptiometry, Photon; Administration, Oral; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; X-Ray Microtomography

2012
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:10

    Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Pilot Projects; Treatment Outcome

2012
Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization.
    Calcified tissue international, 2013, Volume: 92, Issue:1

    Topics: Administration, Oral; Aged; Biopsy; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Regression Analysis; Reproducibility of Results; Treatment Outcome

2013
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
    Bone, 2003, Volume: 32, Issue:4

    Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Bone Density; Collagen; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Time Factors

2003
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.
    Bone, 2003, Volume: 32, Issue:6

    Topics: Administration, Oral; Aged; Analysis of Variance; Biomarkers; Bone Regeneration; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal

2003
Oral weekly ibandronate prevents bone loss in postmenopausal women.
    Journal of internal medicine, 2003, Volume: 254, Issue:2

    Topics: Administration, Oral; Alkaline Phosphatase; Analysis of Variance; Bone Density; Bone Resorption; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Time Factors

2003
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Annals of the rheumatic diseases, 2003, Volume: 62, Issue:10

    Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Collagen; Collagen Type I; Czech Republic; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Norway; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Russia; Statistics, Nonparametric

2003
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:10

    Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome

2003
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2004, Volume: 15, Issue:3

    Topics: Aged; Biopsy; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ibandronic Acid; Ilium; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic

2004
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:1

    Topics: Aged; Bone and Bones; Bone Density; Canada; Collagen; Collagen Type I; Data Interpretation, Statistical; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Femur Neck; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Patient Compliance; Patient Selection; Pelvic Bones; Peptides; Time Factors; Treatment Outcome; United States

2004
Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Aortic Diseases; Bone Density; Bone Resorption; Calcinosis; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Long-Term Care; Middle Aged; Osteoporosis, Postmenopausal

2005
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8

    Topics: Aged; Body Height; Bone and Bones; Bone Density; Diphosphonates; Double-Blind Method; Female; Femur; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Pelvic Bones; Prospective Studies; Risk Factors; Spinal Fractures; Treatment Outcome

2004
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
    The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Area Under Curve; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Feasibility Studies; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides

2005
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:8

    Topics: Absorptiometry, Photon; Administration, Oral; Aged; Bone Density; Collagen; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risk Factors; Spinal Fractures; Spine; Treatment Outcome

2005
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
    Bone, 2005, Volume: 37, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Humans; Ibandronic Acid; Incidence; Internationality; Lumbar Vertebrae; Middle Aged; North America; Osteoporosis, Postmenopausal; Risk; Severity of Illness Index; Spinal Fractures; Time Factors

2005
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.
    The Journal of rheumatology, 2005, Volume: 32, Issue:10

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Upper Gastrointestinal Tract

2005
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
    Annals of the rheumatic diseases, 2006, Volume: 65, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Femur; Hip Joint; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome

2006
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
    Current medical research and opinion, 2005, Volume: 21, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alendronate; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies

2005
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Arthritis and rheumatism, 2006, Volume: 54, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Vitamin D

2006
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
    International journal of clinical practice, 2006, Volume: 60, Issue:8

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Social Support; Treatment Outcome

2006
Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans.
    Annals of the New York Academy of Sciences, 2006, Volume: 1068

    Topics: Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Monitoring, Physiologic; Osteoporosis, Postmenopausal; Peptides

2006
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:3

    Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride

2008
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Current medical research and opinion, 2008, Volume: 24, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome

2008
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
    Joint bone spine, 2008, Volume: 75, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Treatment Outcome

2008
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.
    Clinical rheumatology, 2008, Volume: 27, Issue:8

    Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Longitudinal Studies; Osteoporosis, Postmenopausal

2008
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    The Journal of rheumatology, 2008, Volume: 35, Issue:3

    Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal

2008
The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Bone, 1996, Volume: 19, Issue:5

    Topics: Absorptiometry, Photon; Administration, Oral; Aged; Analysis of Variance; Biomarkers; Body Height; Body Weight; Bone Density; Bone Resorption; Calcium, Dietary; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Forearm; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome

1996
Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
    Scandinavian journal of clinical and laboratory investigation. Supplementum, 1997, Volume: 227

    Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Resorption; Calcitriol; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Placebos; Procollagen

1997
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    The American journal of medicine, 1997, Volume: 103, Issue:4

    Topics: Absorptiometry, Photon; Bone Density; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis, Postmenopausal

1997
Implementation of an osteoporosis research program with a mobile dual-energy X-ray absorptiometry unit: the Montana/Wyoming experience.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1997, Volume: 7, Issue:6

    Topics: Absorptiometry, Photon; Aged; Clinical Trials as Topic; Diphosphonates; Equipment Design; Feasibility Studies; Female; Humans; Ibandronic Acid; Male; Middle Aged; Mobile Health Units; Osteoporosis, Postmenopausal; Patient Selection; Program Evaluation; Rural Population

1997
Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
    Clinical chemistry, 1998, Volume: 44, Issue:11

    Topics: Aged; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Peptides; Sensitivity and Specificity

1998
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1999, Volume: 9, Issue:4

    Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Image Processing, Computer-Assisted; Linear Models; Male; Middle Aged; Osteoporosis, Postmenopausal; Radius; Sensitivity and Specificity; Ulna

1999
Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2001, Volume: 16, Issue:10

    Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Consumer Product Safety; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Drug Tolerance; Female; Hip; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal

2001
Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.
    Bone, 2002, Volume: 30, Issue:1

    Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides

2002

Other Studies

52 other study(ies) available for ibandronic acid and Bone Loss, Perimenopausal

ArticleYear
Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
    Menopause (New York, N.Y.), 2021, 12-20, Volume: 29, Issue:2

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; China; Cost-Benefit Analysis; Denosumab; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Teriparatide; Zoledronic Acid

2021
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022, Volume: 28, Issue:10

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid

2022
Real-world effectiveness of osteoporosis treatments in Germany.
    Archives of osteoporosis, 2022, 08-31, Volume: 17, Issue:1

    Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid

2022
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
    Archives of osteoporosis, 2023, 01-11, Volume: 18, Issue:1

    Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid

2023
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:11

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid

2023
Denosumab Improves Glycaemic Parameters in Postmenopausal Osteoporosis Patients with Combined Type 2 Diabetes Mellitus.
    Cellular and molecular biology (Noisy-le-Grand, France), 2023, Aug-31, Volume: 69, Issue:8

    Topics: Denosumab; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Transcription Factors

2023
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
    BMC musculoskeletal disorders, 2023, Sep-29, Volume: 24, Issue:1

    Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid

2023
Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020, Volume: 31, Issue:1

    Topics: Administration, Oral; Aged; Asian People; Biological Availability; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Race Factors; White People

2020
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Archives of osteoporosis, 2017, Dec-21, Volume: 13, Issue:1

    Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bulgaria; Denosumab; Diphosphonates; Female; Femur Neck; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies

2017
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019, Volume: 30, Issue:3

    Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Republic of Korea; Retrospective Studies; Risedronic Acid

2019
[Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: a pilot study].
    Terapevticheskii arkhiv, 2013, Volume: 85, Issue:5

    Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cartilage; Diphosphonates; Disability Evaluation; Female; Humans; Ibandronic Acid; Locomotion; Middle Aged; Osteoarthritis, Knee; Osteoporosis, Postmenopausal; Pain; Pain Measurement; Pilot Projects; Severity of Illness Index

2013
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes

2014
Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:7

    Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Evaluation; Female; Humans; Ibandronic Acid; Injections, Intravenous; Injections, Subcutaneous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Teriparatide; Treatment Outcome

2014
Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, Volume: 26, Issue:3

    Topics: Bone Density; Bone Density Conservation Agents; Calcaneus; Case-Control Studies; Densitometry; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Homocysteine; Humans; Ibandronic Acid; Leptin; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome; Ultrasonography

2015
Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
    Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Surveys and Questionnaires

2015
Successful conservative treatment: multiple atypical fractures in osteoporotic patients after bisphosphate medication: a unique case report.
    Medicine, 2015, Volume: 94, Issue:5

    Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femur; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal

2015
Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
    Minerva endocrinologica, 2015, Volume: 40, Issue:3

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid

2015
Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Endokrynologia Polska, 2016, Volume: 67, Issue:2

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Thiophenes

2016
Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis.
    Journal of orthopaedic surgery (Hong Kong), 2016, Volume: 24, Issue:3

    Topics: Absorptiometry, Photon; Aged; Asian People; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femur; Humans; Ibandronic Acid; Japan; Middle Aged; Osteoporosis, Postmenopausal; Vitamin D

2016
Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017, Volume: 28, Issue:4

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Databases, Factual; Denosumab; Diphosphonates; Drug Utilization; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Teriparatide; United States; Zoledronic Acid

2017
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017, Volume: 28, Issue:6

    Topics: Acute-Phase Reaction; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Risk Factors; Severity of Illness Index; Zoledronic Acid

2017
Ibandronate: is there an effect on nonvertebral fractures?
    Clinical rheumatology, 2008, Volume: 27, Issue:10

    Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Meta-Analysis as Topic; Osteoporosis, Postmenopausal

2008
Acute phase reaction with intravenous ibandronate.
    The American journal of medicine, 2008, Volume: 121, Issue:9

    Topics: Acute-Phase Reaction; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal

2008
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    The American journal of managed care, 2008, Volume: 14, Issue:9

    Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Ibandronic Acid; Markov Chains; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Risk Assessment; Risk Factors; United States

2008
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:1

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Epidemiologic Methods; Female; France; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures

2010
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Journal of women's health (2002), 2009, Volume: 18, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Surveys and Questionnaires

2009
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:6

    Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; United States

2010
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.
    Clinical interventions in aging, 2009, Volume: 4

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Gastrointestinal Agents; Gastrointestinal Tract; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Surveys and Questionnaires

2009
Postmenopausal osteoporosis: another approach to management.
    The Journal of family practice, 2010, Volume: 59, Issue:6

    Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Medication Adherence; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risk Assessment; Secondary Prevention; Zoledronic Acid

2010
When do bisphosphonates make the most sense?
    The Journal of family practice, 2011, Volume: 60, Issue:1

    Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; United States; Women's Health

2011
The efficiency of Bonviva (Ibadronate) in women with pre-post menopause.
    Medicinski arhiv, 2010, Volume: 64, Issue:4

    Topics: Absorptiometry, Photon; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal

2010
Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.
    Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:3

    Topics: 25-Hydroxyvitamin D 2; Aged; Bone Density Conservation Agents; Calcifediol; Calcium; Consensus; Diphosphonates; Drug Resistance; Electronic Health Records; Evidence-Based Medicine; Female; Guideline Adherence; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Zoledronic Acid

2011
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:2

    Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid

2012
Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.
    Clinical rheumatology, 2011, Volume: 30, Issue:12

    Topics: Aged; Bone Density Conservation Agents; Croatia; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires

2011
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
    Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:5

    Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Injections, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Retrospective Studies; Risedronic Acid

2012
Question: In postmenopausal women with osteoporosis is once monthly oral ibandronate (150 mg) therapy preferred to once weekly oral bisphosphonate therapy.
    The Journal of the Oklahoma State Medical Association, 2012, Volume: 105, Issue:3

    Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Preference; Randomized Controlled Trials as Topic

2012
Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Clinical drug investigation, 2013, Volume: 33, Issue:2

    Topics: Acute-Phase Reaction; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Zoledronic Acid

2013
Injectable drug dampens bone loss.
    Health news (Waltham, Mass.), 2003, Volume: 9, Issue:12

    Topics: Bone Density; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2003
Ibandronate and prevention of postmenopausal osteoporosis.
    Annals of the rheumatic diseases, 2004, Volume: 63, Issue:5

    Topics: Bone Density; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2004
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
    Treatments in endocrinology, 2005, Volume: 4, Issue:2

    Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid

2005
[Monthly tablet].
    Krankenpflege Journal, 2005, Volume: 43, Issue:1-3

    Topics: Aged; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Europe; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance

2005
Ibandronate (Boniva): a new oral bisphosphonate.
    Obstetrics and gynecology, 2005, Volume: 106, Issue:2

    Topics: Administration, Oral; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2005
[Postmenopausal osteoporosis].
    Krankenpflege Journal, 2005, Volume: 43, Issue:4-6

    Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Treatment Outcome

2005
[Ibandronate once a month].
    Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:1

    Topics: Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2006
[Monthly tablet in postmenopausal osteoporosis].
    Krankenpflege Journal, 2005, Volume: 43, Issue:7-10

    Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal

2005
Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.
    Current drug metabolism, 2006, Volume: 7, Issue:7

    Topics: Bone Density Conservation Agents; Computer Simulation; Diphosphonates; Female; Humans; Ibandronic Acid; Models, Biological; Osteoporosis, Postmenopausal

2006
Compliance with treatment for osteoporosis.
    Lancet (London, England), 2006, Nov-11, Volume: 368, Issue:9548

    Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Patient Compliance

2006
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Current medical research and opinion, 2006, Volume: 22, Issue:12

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Interviews as Topic; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid; United States

2006
Use of intravenous bisphosphonates in osteoporosis.
    Current osteoporosis reports, 2007, Volume: 5, Issue:1

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Patient Compliance; Zoledronic Acid

2007
Osteoporosis medication profile preference: results from the PREFER-US study.
    Health expectations : an international journal of public participation in health care and health policy, 2007, Volume: 10, Issue:3

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Internet; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Socioeconomic Factors; Time Factors

2007
Osteoporosis: non-hormonal treatment.
    Climacteric : the journal of the International Menopause Society, 2007, Volume: 10 Suppl 2

    Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health

2007
Ibandronic acid. BM 210955, RPR 102289A, methylpentylaminopropylidene, Bondronat Bonviva.
    Drugs in R&D, 1999, Volume: 1, Issue:3

    Topics: Animals; Diphosphonates; Dogs; Drug Interactions; Drugs, Investigational; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal

1999
chemdatabank.com